title: [TLR4 expression of human PBMC treated by BCG and its role of immune activation].
abstract: OBJECTIVE
  To investigate TLR4 expression of human peripheral blood mononuclear cells (hPBMC) treated with BCG and its role of immune activation.
  
  
  METHODS
  hPBMC were treated with BCG in vitro. TLR4 expression were detected by flow cytometry, IFN-γ and TNF-α expression of hPBMC in both BCG stimulated group and the control group were detected by ELISA.
  
  
  RESULTS
  The expression of TLR4 in hPBMC treated with BCG was stronger than the control group significantly (P<0.01) and increased with the time. In 72 h the TLR4 expression of BCG group was (44.73 ± 0.0066)%, while the control group was (1.02 ± 0.0024)%. BCG can promote hPBMC proliferation, and this enhancement was time-dependent. In 24 h, 48 h and 72 h IFN-γ and TNF-α expression of BCG group were significantly higher than the control group(P<0.05), and this enhancement was time-dependent.
  
  
  CONCLUSIONS
  BCG can on enhance TLR4 expression and promote immune activation of hPBMC.
authors: Based Medical Research Center, Tianjin Medical University, Tianjin 300070, China.
authors: Rui
authors: R
authors: Sun
authors: Xiong
authors: X
authors: Yang
authors: Er-Lin
authors: EL
authors: Sun
authors: Rui-Fa
authors: RF
authors: Han
mesh_terms: D001500:BCG Vaccine / Q000276:immunology*; D002478:Cells, Cultured; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000276:immunology* / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D001500:BCG Vaccine; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma